HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: 287/4/H1516    most recent 00947.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Langenickel, T. H. Articles by Bader, M. Search for Related Content PubMed PubMed Citation Articles by Langenickel, T. H. Articles by Bader, M.

Rat corin gene: molecular cloning and reduced expression in experimental heart failure

¹Max-Delbrueck-Center for Molecular Medicine, Berlin 13092; and ²Franz-Volhard-Klinik, Charité Campus Berlin-Buch, Humboldt-University, Berlin 13125, Germany

Submitted 6 October 2003 ; accepted in final form 12 May 2004

	ABSTRACT

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Stored cardiac pro-atrial natriuretic peptide (pro-ANP) is converted to ANP and released upon stretch from the atria into the circulation. Corin is a serin protease with pro-ANP-converting properties and may be the rate-limiting enzyme in ANP release. This study was aimed to clone and sequence corin in the rat and to analyze corin mRNA expression in heart failure when ANP release upon stretch is blunted. Full-length cDNA of rat corin was obtained from atrial RNA by RT-PCR and sequenced. Tissue distribution as well as regulation of corin mRNA expression in the atria were determined by RT-PCR and RNase protection assay. Heart failure was induced by an infrarenal aortocaval shunt. Stretch was applied to the left atrium in a working heart modus, and ANP was measured in the perfusates. The sequence of rat corin cDNA was found to be 93.6% homologous to mouse corin cDNA. Corin mRNA was expressed almost exclusively in the heart with highest concentrations in both atria. The aortocaval shunt led to cardiac hypertrophy and heart failure. Stretch-induced ANP release was blunted in shunt animals (control 1,195 ± 197 fmol·min^–1·g^–1; shunt: 639 ± 99 fmol·min^–1·g^–1, P < 0.05). Corin mRNA expression was decreased in both atria in shunt animals [right atrium: control 0.638 ± 0.004 arbitrary units (AU), shunt 0.566 ± 0.014 AU, P < 0.001; left atrium: control 0.564 ± 0.009 AU, shunt 0.464 ± 0.009 AU, P < 0.001]. Downregulation of atrial corin mRNA expression may be a novel mechanism for the blunted ANP release in heart failure.

gene expression; atrial natiuretic factor

The plasma concentrations as well as cardiac tissue concentrations and ANP mRNA expression are increased in experimental heart failure induced by volume overload in the rat (1, 3, 16). However, the ANP response to acute volume expansion is blunted in cardiac hypertrophy as well as heart failure (18, 23, 25). It is unclear whether the impaired ANP release in heart failure is a result of neurohormonal suppression or due to an inhibition of the release mechanism itself.

The critical step during the ANP release is the conversion of pro-ANP to ANP. Recently, corin, a membrane-bound type II serin protease, also known as LRP4, has been identified as a pro-ANP-converting enzyme (21, 27). Corin converts pro-ANP(1–126) into ANP(99–126) by cleaving pro-ANP specifically behind arginine at position 98 in vitro (28) and in a murine cardiac myocytic cell line, HL-5 (26). Corin was shown to be expressed in the heart, testis, and kidney of mice, but cardiac expression was predominant (21, 27). Corin is also expressed in the human heart (11). Corin and NPs are coexpressed during development suggesting that corin might be important for conversion of pro-ANP to ANP at this stage as well (27).

However, no information is available on corin in the rat, neither on the sequence nor on the tissue distribution of corin mRNA expression. It is further unknown as to whether corin mRNA expression is regulated and related to a blunted ANP release in heart failure. Therefore, this study was aimed to clone and sequence rat corin cDNA, determine the expression pattern in several organs, and correlate the corin mRNA level at the site of highest synthesis, the atria, to ANP release upon stretch in experimental heart failure due to chronic volume overload in the rat.

	METHODS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Animal Studies

Experimental heart failure model in the rat. The infrarenal aortocaval shunt in male Wistar rats was used as a model of volume overload-induced heart failure as previously described (8). Sham-operated rats used as controls were treated identically except that no puncture of the vessels was performed. Four weeks after surgery, two separate sets of sham- and shunt-operated rats were used for either in vivo hemodynamic measurements and molecular biology studies or working heart studies. The study was carried out in accordance with the local authorities and conformed with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996).

Hemodynamic measurements. Animals were anesthetized with chloralhydrate, and a polyethylene-50 tubing catheter was inserted via the right carotid artery into the left ventricle for measurement of mean arterial and end-diastolic pressures. Central venous pressure was measured by cannulating the left jugular vein. Left ventricular contractility (dP/dt_max) was obtained from the ventricular pressure curves, which were converted with a Gould differentiator (G4615). All pressures were registered with a Statham P23 XL transducer and a Gould AMP 4600 amplifier. Heart rate was derived from the arterial blood pressure signal.

Molecular Biology Studies

RNA preparation. After the rats were euthanized, the hearts were rapidly dissected, washed in ice-cold diethylpyrocarbonate-treated water, and weighed, and the four heart chambers were immediately separated and frozen in liquid nitrogen. The organs were kept at –80°C until RNA extraction. Total RNA was extracted from several organs of control animals as well as from the atria of control and shunt animals with TRIzol reagent (Invitrogen, Life Technologies) according to the manufacturer's protocol.

Molecular cloning of rat corin. First-strand cDNA was generated from 5 µg atrial rat RNA by reverse transcription (RT-PCR Kit, Stratagene) using an oligo-dT primer. Corin was amplified by PCR from 5 µl first-strand cDNA using specific primers (forward primer 5'-CTTGGAGTCGGAGGCTCGGAC-3' and reverse primer 5'-TTACCATAGAGCTCCAGATGTCTC-3', BioTez) and a mixture of polymerases with proofreading activity (AccuTaq, Sigma). The obtained full-length corin cDNA was purified by gel electrophoresis, elongated by incubation with Taq polymerase for 30 min at 72°C, and cloned into the pGEM-T vector (Promega). Corin was sequenced twice and stepwise starting with standard SP6 and T7 primers (Invitek). The obtained corin cDNA sequence was compared with the available Genbank sequence of the rat genome, and three additional corin fragments were amplified by RT-PCR from atrial RNA and sequenced to rule out mistakes in sequencing or PCR amplication (forward primer 1 5'-TTCCTCCTGCTTGTGCTCATC-3' and reverse primer 1 5'-CTTGTCCACACAGTCATGGTC-3'; forward primer 2 5'-GTGGAATGCAGAAGTGGACAG-3' and reverse primer 2 5'-GTGCTCCCATTGAGATTCTC-3'; and forward primer 3 5'-TACCAAGCAAGACTGTGGTC-3' and reverse primer 3 5'-GACACATTGCTGTACACTCC-3', BioTez).

Analysis of corin mRNA expression. Corin (317 nt) and GAPDH (187 nt) were amplified by RT-PCR using the primers corin5 5'-CAAATTCTGCCCTACCACAGCAC-3', corin3 5'-GGCGTCGCTGTTATTCTCAGTG-3', GAPDH5 5'-CCATGGAGAAGGCTGGGG-3', and GAPDH3 5'-CAAAGTTGTCATGGATGACC-3' and cloned into the pGEM-T vector (Promega). The plasmids were digested with PvuII, and antisense probes were [³²P]UTP labeled by in vitro transcription (Promega). Corin mRNA expression was measured by a RNase protection assay according to the manufacturer's protocol (RPA III kit, Ambion) using 20 µg total RNA and 35,000 counts/min antisense probe each. Protected fragments were separated on a polyacrylamide gel and detected by a Fuji phosphoimager (Fujix BAS 2000, Fuji). For semiquantitative determination of corin mRNA, the signals were normalized to GAPDH mRNA expression.

Measurement of ANP Release in a Working Heart Preparation

The thorax was opened under chloralhydrate anesthesia, and the heart was rapidly removed. The aorta and left atrium (LA) were cannulated, and the heart was perfused with a modified Krebs-Henseleit solution (2.1 mM MgSO₄, 118 mM NaCl, 4.7 mM KCl, 60 µM Na-EDTA, 24.7 mM NaHCO₃, 1.5 mM CaCl₂, and 11.1 mM glucose, Merck) at 37°C using an isolated heart apparatus (Type 830, Hugo Sachs; March-Hugstetten, Germany). The solution was saturated with 95% O₂-5% CO₂ (pH 7.4). For equilibration and the baseline period, hearts were perfused retrograde via the aorta at a constant perfusion pressure (65 mmHg). The perfusion pressure was kept constant throughout the experiment. Baseline values for ANP secretion were obtained after 30-min equilibration while the LA pressure (LAP) was 0 mmHg. ANP release was stimulated by an elevation of the LAP to 10 mmHg. Perfusates were collected on ice, immediately frozen, and stored at –80°C. ANP concentration was measured by radioimmunoassay as described (16) and normalized to heart weight. The antibody used in this study was raised agaist the COOH-terminal rat ANP, thus detecting pro-ANP as well as COOH-terminal ANP.

Statistical Analysis

The differences between the two groups were evaluated with the paired Student's t-test using StatView software. The significance level was set at P < 0.05. All data are expressed as means ± SE.

	RESULTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Molecular Cloning of Rat Corin

Rat corin cDNA was cloned and sequenced (Genbank accession number AY251285), and the encoded protein was found to be 93% homologous to mouse and 85% homologous to human corin (Fig. 1). Functional important domains such as the putative transmembrane domain and ligand-binding motifs were found to be highly conserved.

View larger version (94K): [in this window] [in a new window]   Fig. 1. Amino acid sequences of rat, mouse, and human corin. Consensus shows amino acids identical in at least two corins. The putative transmembrane domain and the ligand binding motifs (SDE and similar) are underlined.

Tissue Distribution of Corin mRNA

Tissue distribution of corin mRNA was analyzed by Northern blot analysis and RT-PCR. In Northern blot analysis, corin mRNA was exclusively detectable in the heart, and there with highest concentrations in the right atrium (RA; Fig. 2A). RT-PCR confirmed the predominant localization to the heart but also identified additional expression in the kidney, aorta, brain, and testis (Fig. 2B). Expression in the aorta and brain has not previously been demonstrated in mice and humans.

View larger version (72K): [in this window] [in a new window]   Fig. 2. Tissue distribution of corin mRNA. A: Northern blot analysis demonstrated corin mRNA expression in the heart, and there with highest concentration in both atria. B: RT-PCR analysis confirmed major expression in the heart but also detected expression in the aorta, kidney, brain, and testis.

Four weeks after shunt induction, heart weight was significantly increased compared with controls (598 ± 18 vs. 310 ± 5 mg/100 g body wt, P < 0.01; Fig. 3A). All four heart chambers contributed to the elevated heart weight, demonstrating biventricular hypertrophy due to chronic volume overload. In parallel, dP/dt_max was impaired (3,650 ± 254 vs. 4,911 ± 242 mmHg/s, P < 0.05; Fig. 3B), whereas left ventricular end-diastolic pressure (LVEDP) as well as central venous pressure (CVP) were elevated, in rats with aortocaval shunt compared with controls (LVEDP: 15.2 ± 2.5 vs. 5.4 ± 1.3 mmHg, P < 0.01; Fig. 3C; CVP: 9.5 ± 0.9 vs. 1.6 ± 0.5 mmHg, P < 0.01; Fig. 3D).

View larger version (10K): [in this window] [in a new window]   Fig. 3. Hemodynamic evaluation of heart failure induced by aortocaval shunt. A: relative heart weight (HW) is increased in animals with an aortocaval shunt. bw, Body weight. **P < 0.01. B: left ventricular contractility (dP/dtmax) is reduced in rats with an aortocval shunt. *P < 0.05. C: left ventricular end-diastolic pressure (LVEDP) is increased in animals with an aortocaval shunt. **P < 0.01. D: central venous pressure (CVP) is increased in animals with an aortocaval shunt. **P < 0.01.

To test the hypothesis that ANP release from isolated hearts is blunted in heart failure, LA stretch was applied by elevating the left intra-atrial pressure to 10 mmHg (Fig. 4A). ANP release during baseline was not different between shunt-operated and control rats (control: 359 ± 52 fmol·min^–1·g^–1, shunt: 355 ± 32 fmol·min^–1·g^–1; Fig. 4B). LA stretch significantly increased ANP secretion from normal hearts, whereas ANP release was blunted compared with baseline values in hearts from rats with aortocaval shunt (control 1,195 ± 197 fmol·min^–1·g^–1, shunt 639 ± 99 fmol·min^–1·g^–1, P < 0.05; Fig. 4B).

View larger version (11K): [in this window] [in a new window]   Fig. 4. Atrial natriuretic peptide (ANP) release after stretch. A: after a 30-min baseline period, left atrial pressure (LAP) was increased from 0 to 10 mmHg in a Langendorff isolated heart perfusion, and basal ANP release was measured during the baseline period. B: ANP release due to an increase in LAP is significantly lower in animals with an aortocaval shunt compared with controls. *P < 0.05. Baseline ANP release was not different in both groups.

Regulation of LA and RA corin mRNA levels were studied in experimental heart failure by ribonuclease protection assay. Both LA and RA corin mRNA concentrations were found to be significantly decreased in rats with an aortocaval shunt compared with controls (LA: 0.464 ± 0.009 vs. 0.564 ± 0.009 AU, P < 0.001; Fig. 5; RA: 0.566 ± 0.014 vs. 0.638 ± 0.004 AU, P < 0.001; Fig. 6).

View larger version (27K): [in this window] [in a new window]   Fig. 5. Left atrial corin mRNA expression detected by RNase protection assay (bottom) is decreased in animals with aortocaval shunt. AU, arbitrary units. ***P < 0.001.

View larger version (24K): [in this window] [in a new window]   Fig. 6. Right atrial corin mRNA expression detected by RNase protection assay (bottom) is decreased in animals with aortocaval shunt. ***P < 0.001.

	DISCUSSION

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

The major stimulus for ANP release is acute volume expansion (15), leading to atrial stretch. After acute volume load, a rapid increase of circulating ANP plasma levels occurs within a few minutes (12). The coexpression of ANP and corin in both atria points toward a possible function of corin for the cleavage of pro-ANP upon atrial stretch in the rat heart in vivo.

In several models of experimental heart failure as well as in human heart failure, ANP release after either acute volume load or exercise is blunted (7, 13, 17, 18, 24, 25). Willenbrock et al. (25) suggested that the ANP system is impaired in rats with an acute aortocaval shunt and that the activation of the angiotensin system contributes to the impairment of the ANP system. Inadequate ANP secretion upon stimulation may thereby contribute to fluid retention during the progression of heart failure.

However, it is unclear whether the impaired ANP release in heart failure is a result of neurohormonal suppression or due to changes in atrial cardiomyocytes themselves. We investigated the stretch-induced ANP release in isolated hearts from normal rats and rats with chronic volume overload due to aortocaval shunt. These animals were characterized by significant cardiac hypertrophy in parallel with impaired ventricular function. Whereas baseline secretion of ANP was not different between both groups, ANP release after LA stretch was significantly reduced in animals with shunt. Because the pressure was subphysiological at baseline compared with intact animals and thereby the stimulus for ANP release was minimal under these conditions, we assumed that the pro-ANP-converting ability of corin was not used to full capacity. Only after application of atrial stretch we found a significantly blunted ANP release from hearts of heat failure rats, suggesting that reduced corin expression might be the rate-limiting factor for ANP secretion after atrial stretch. The atrial ANP mRNA expression level as well as ANP concentrations have been measured in rats with an aortocaval shunt. Langenickel et al. (16) showed that ANP mRNA was upregulated in the LA of shunted rats, whereas the RA ANP mRNA expression remained unchanged. Willenbrock et al. (25) found unchanged ANP mRNA as well as ANP concentration in both the LA and RA in this heart failure model. These data suggest that the blunted ANP release we observed in shunt animals was neither due to impaired synthesis nor depleted storage vesicles of ANP.

In experimental heart failure, the atrial corin mRNA level was decreased in parallel to a blunted ANP release upon stretch. These data indicate for the first time, that corin, which has been shown to cleave pro-ANP in vitro, might also be a rate-limiting mechanism for ANP release in vivo. It has been shown that pro-ANP is activated during secretion, probably by corin located on the cell surface (9, 11, 19). Thus downregulated corin expression might be responsible for the blunted release of active ANP in heart failure. In fact, increased circulating amounts of unprocessed ANP precursor are found in heart failure patients and animal models (2, 20, 22). It has been shown that ventricles induce ANP expression in heart failure and release mostly the precursor pro-ANP into the circulation (20). The low amount of corin expression (Fig. 2A) may cause this incomplete processing in ventricles. Thus our data indicate that the observed high levels of circulating ANP precursor in heart failure are derived from insufficient availability of corin in atria and ventricles. To date, no mechanisms regulating the gene expression and/or activity of corin have been identified. Thus the relation between congestive heart failure and the downregulation of corin needs to be further investigated.

	GRANTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
This study was supported by research fellowships from the Max-Delbrueck-Center for Molecular Medicine (to T. H. Langenickel and I. Pagel) and by a grant from the "Verbund Klinische Pharmakologie Berlin-Brandenburg" (to T. H. Langenickel).

	ACKNOWLEDGMENTS

 
Present address of I. Pagel: National Heart, Lung, and Blood Institute, Cardiovascular Branch, Bldg. 10/7B02, 9000 Rockville Pike, Bethesda, MD 20892.

Present address of R. Willenbrock: St. Elisabeth Hospital, Mauerstrasse 5, 06110 Halle (Saale), Germany.

	FOOTNOTES

 

Address for reprint requests and present address of T. Langenickel: National Heart, Lung, and Blood Institute, 50 Center Dr., Bldg. 50/4529, Bethesda, MD 20892 (E-mail: langenit{at}nhlbi.nih.gov)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	REFERENCES

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 

1. Abassi Z, Burnett JC Jr, Grushka E, Hoffman A, Haramati A, and Winaver J. Atrial natriuretic peptide and renal cGMP in rats with experimental heart failure. Am J Physiol Regul Integr Comp Physiol 261: R858–R864, 1991.[Abstract/Free Full Text]
2. Arendt RM, Gerbes AL, Ritter D, and Stangl E. Molecular weight heterogeneity of plasma-ANF in cardiovascular disease. Klin Wochenschr 64: 97–102, 1986.
3. Brown LA, Nunez DJ, and Wilkins MR. Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. J Clin Invest 92: 2702–2712, 1993.[Web of Science][Medline]
4. Bruneau BG and de Bold AJ. Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1. Cardiovasc Res 28: 1519–1525, 1994.[Web of Science][Medline]
5. De Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science 230: 767–770, 1985.[Abstract/Free Full Text]
6. De Bold AJ, Bruneau BG, Kuroski-de-Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31: 7–18, 1996.[CrossRef][Web of Science][Medline]
7. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, and Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26: 438–445, 1995.[Abstract]
8. Garcia R and Diebold S. Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res 24: 430–432, 1990.[Abstract/Free Full Text]
9. Glembotski CC, Dixon JE, and Gibson TR. Secretion of atrial natriuretic factor-(1–98) by primary cardiac myocytes. J Biol Chem 263: 16073–16081, 1988.[Abstract/Free Full Text]
10. Hasegawa K, Fujiwara H, Itoh H, Nakao K, Fujiwara T, Imura H, and Kawai C. Light and electron microscopic localization of brain natriuretic peptide in relation to atrial natriuretic peptide in porcine atrium. Circulation 84: 1203–1209, 1991.[Abstract/Free Full Text]
11. Hooper JD, Scarman AL, Clarke BE, Normyle JF, and Antalis TM. Localization of the mosaic transmembrane serine protease to heart myocytes. Eur J Biochem 267: 6931–6937, 2000.[Web of Science][Medline]
12. Kato J, Kida O, Higa T, Sasaki A, Kondo K, Miyata A, Kangawa K, Matsuo H, and Tanaka K. Increase in plasma atrial natriuretic polypeptide (ANP) following sodium load in anesthetized rats. Life Sci 39: 493–497, 1986.[CrossRef][Web of Science][Medline]
13. Keller N, Larsen J, Sykulski R, Storm T, and Thamsborg G. Atrial natriuretic factor during exercise in patients with congestive heart failure. Acta Endocrinol 118: 168–172, 1988.
14. Koller KJ and Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 86: 1081–1087, 1992.[Abstract/Free Full Text]
15. Lang RE, Thölken H, Ganten D, Luft FC, Ruskoaho H, and Unger T. Atrial natriuretic factor-a circulating hormone stimulated by volume loading. Nature 314: 264–266, 1985.[CrossRef][Medline]
16. Langenickel T, Pagel I, Höhnel K, Dietz R, and Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol 278: H1500–H1506, 2000.[Abstract/Free Full Text]
17. Moe GW, Grima EA, Angus C, Wong NL, Hu DC, Howard RJ, and Armstrong PW. Response of atrial natriuretic factor to acute and chronic increases of atrial pressures in experimental heart failure in dogs. Circulation 83: 1780–1787, 1991.[Abstract/Free Full Text]
18. Redfield MM, Edwards BS, McGoon MD, Heublein DM, Aarhus LL, and Burnett JC Jr. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation 80: 651–657, 1989.[Abstract/Free Full Text]
19. Thibault G, Haile-Meskel H, Wrobel-Konrad E, Ballak M, Garcia R, Genest J, and Cantin M. Processing of the atrial natriuretic factor propeptide by atrial cardiocytes as revealed by immunocryoultramicrotomy. Endocrinology 124: 3109–3116, 1989.[Abstract/Free Full Text]
20. Thibault G, Nemer M, Drouin J, Lavigne JP, Ding J, Charbonneau C, Garcia R, Genest J, Jasmin G, Sole M, and Cantin M. Ventricles as a major site of atrial natriuretic factor synthesis and release in cardiomyopathic hamsters with heart failure. Circ Res 65: 71–82, 1989.[Abstract/Free Full Text]
21. Tomita Y, Kim DH, Magoori K, Fujino T, and Yamamoto T. A novel low-density lipoprotein receptor-related protein with type II membrane protein-like structure is abundant in heart. J Biochem (Tokyo) 124: 784–789, 1998.[Abstract/Free Full Text]
22. Vollmar AM, Reusch C, Kraft W, and Schulz R. Atrial natriuretic peptide concentration in dogs with congestive heart failure, chronic renal failure, and hyperadrenocorticism. Am J Vet Res 52: 1831–1834, 1991.[Web of Science][Medline]
23. Volpe M, Tritto C, DeLuca N, Rubattu S, Mele AF, Lembo G, Enea I, DeCampora P, Rendina V, Romano M, Trimarco B, and Condorelli M. Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. Circulation 86: 1800–1809, 1992.[Abstract/Free Full Text]
24. Volpe M, Tritto C, Luca ND, Mele AF, Lembo G, Rubattu S, Romano M, Campora PD, Enea I, Ricciardelli B, Trimarco B, and Condorelli M. Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J Clin Invest 88: 1481–1489, 1991.[Web of Science][Medline]
25. Willenbrock R, Scheuermann M, Thibault G, Haass M, Höhnel K, Bohlender J, Luft FC, and Dietz R. Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt. Cardiovasc Res 42: 733–742, 1999.[Abstract/Free Full Text]
26. Wu F, Yan W, Pan J, Morser J, and Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem 277: 16900–16905, 2002.[Abstract/Free Full Text]
27. Yan W, Sheng N, Seto M, Morser J, and Wu Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 274: 14926–14935, 1999.[Abstract/Free Full Text]
28. Yan W, Wu F, Morser J, and Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 97: 8525–8529, 2000.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. N. Hume, J. Buttgereit, A. M. Al-Awadhi, S. S. Al-Suwaidi, A. John, M. Bader, M. C. Seabra, L. Al-Gazali, and B. R. Ali Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux Hum. Mol. Genet., January 15, 2009; 18(2): 267 - 277. [Abstract] [Full Text] [PDF]

				D. L. Dries Relevance of Molecular Forms of Brain Natriuretic Peptide for Natriuretic Peptide Research Hypertension, May 1, 2007; 49(5): 971 - 973. [Full Text] [PDF]

				D. M. Heublein, B. K. Huntley, G. Boerrigter, A. Cataliotti, S. M. Sandberg, M. M. Redfield, and J. C. Burnett Jr Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide Hypertension, May 1, 2007; 49(5): 1114 - 1119. [Abstract] [Full Text] [PDF]

				J. C. Burnett Jr and T. M. Olson Natriuretic Peptides and Myocardial Structure: Insights From Population Genetics Hypertension, April 1, 2007; 49(4): 765 - 766. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 287/4/H1516    most recent 00947.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Langenickel, T. H. Articles by Bader, M. Search for Related Content PubMed PubMed Citation Articles by Langenickel, T. H. Articles by Bader, M.